收费全文 | 3449篇 |
免费 | 382篇 |
国内免费 | 31篇 |
耳鼻咽喉 | 25篇 |
儿科学 | 192篇 |
妇产科学 | 74篇 |
基础医学 | 505篇 |
口腔科学 | 204篇 |
临床医学 | 446篇 |
内科学 | 637篇 |
皮肤病学 | 62篇 |
神经病学 | 190篇 |
特种医学 | 233篇 |
外科学 | 471篇 |
综合类 | 77篇 |
一般理论 | 1篇 |
预防医学 | 298篇 |
眼科学 | 61篇 |
药学 | 179篇 |
中国医学 | 4篇 |
肿瘤学 | 203篇 |
2022年 | 25篇 |
2021年 | 41篇 |
2020年 | 36篇 |
2019年 | 39篇 |
2018年 | 86篇 |
2017年 | 72篇 |
2016年 | 58篇 |
2015年 | 86篇 |
2014年 | 128篇 |
2013年 | 170篇 |
2012年 | 144篇 |
2011年 | 127篇 |
2010年 | 138篇 |
2009年 | 145篇 |
2008年 | 100篇 |
2007年 | 120篇 |
2006年 | 110篇 |
2005年 | 96篇 |
2004年 | 89篇 |
2003年 | 77篇 |
2002年 | 85篇 |
2001年 | 79篇 |
2000年 | 70篇 |
1999年 | 70篇 |
1998年 | 119篇 |
1997年 | 106篇 |
1996年 | 119篇 |
1995年 | 77篇 |
1994年 | 93篇 |
1993年 | 53篇 |
1992年 | 50篇 |
1991年 | 63篇 |
1990年 | 60篇 |
1989年 | 73篇 |
1988年 | 66篇 |
1987年 | 55篇 |
1986年 | 71篇 |
1985年 | 59篇 |
1984年 | 42篇 |
1983年 | 43篇 |
1982年 | 41篇 |
1981年 | 35篇 |
1980年 | 40篇 |
1979年 | 39篇 |
1978年 | 29篇 |
1977年 | 34篇 |
1976年 | 42篇 |
1975年 | 32篇 |
1973年 | 25篇 |
1972年 | 30篇 |
![点击此处可从《Annals of the rheumatic diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Methods: 19 subjects with clinical unilateral hip osteoarthritis and 19 healthy controls were investigated. The subjects performed a stepping task during which recordings were obtained using surface electromyograms from the hip abductors, and kinetic data were obtained from a dual force platform.
Results: Subjects with clinical hip osteoarthritis had higher gluteus medius activation than the healthy older adults (p=0.037). In addition, there were no differences in the magnitude of gluteus medius activation between the sides (p=0.733). There was no difference in the force platform data between the groups (p=0.078).
Conclusions: The increased magnitude of gluteus medius activation in the group with hip osteoarthritis is evidence of a muscular dysfunction associated with hip disease. This has implications for the progressive nature of the disease and for its conservative management.
相似文献Background:
Monoamine reuptake inhibitors exhibit unique clinical profiles that reflect distinct engagement of the central nervous system (CNS) transporters.Methods:
We used a translational strategy, including rodent pharmacokinetic/pharmacodynamic modeling and positron emission tomography (PET) imaging in humans, to establish the transporter profile of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.Results:
TD-9855 was a potent inhibitor of norepinephrine (NE) and serotonin 5-HT uptake in vitro with an inhibitory selectivity of 4- to 10-fold for NE at human and rat transporters. TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7ng/mL and 50.8ng/mL, respectively, consistent with modest selectivity for NET in vivo.Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5ng/mL and 23.9ng/mL, respectively. A single-dose, open-label PET study (4–20mg TD-9855, oral) was conducted in eight healthy males using the radiotracers [11C]-3-amino-4- [2-[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile for SERT and [11C]-(S,S)-methylreboxetine for NET. The long pharmacokinetic half-life (30–40h) of TD-9855 allowed for sequential assessment of SERT and NET occupancy in the same subject. The plasma EC50 for NET was estimated to be 1.21ng/mL, and at doses of greater than 4mg the projected steady-state NET occupancy is high (>75%). After a single oral dose of 20mg, SERT occupancy was 25 (±8)% at a plasma level of 6.35ng/mL.Conclusions:
These data establish the CNS penetration and transporter profile of TD-9855 and inform the selection of potential doses for future clinical evaluation. 相似文献![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)